WestGene to Advance Clinical Trials Following Dual IND Approvals for World's First EB Virus-Related mRNA Therapeutic Cancer Vaccine

WestGene Biopharma's mRNA therapeutic cancer vaccine, WGc-043, receives dual IND approvals from China's NMPA and the US FDA, marking the world's first for EBV-related cancers. Featuring AI-assisted antigen screening and an advanced delivery system, WGc-043 targets EBV-positive solid tumors and hematologic malignancies, with promising safety and efficacy data from previous trials.